In Moscow alone, according to the Russian Association of Phlebologists, CVI affects 67% of the active working-age population. Among the factors leading to the development of venous leg ulcers, the most common is chronic venous insufficiency accounting for more than 50%. Trophic lesions against a background of CVI cause long-term disability and invalidity in people in their most able-bodied and active ages, lead to considerable limitations in the basic spheres of life, from the ability to work to capacity for independent movement and self-care, thus reducing the quality of life. The total number of patients with a history of or currently suffering from venous trophic disorders of the lower limbs is 6% of the population. The incidence is increased in patients in older age groups, and complete elimination of the disease can only be achieved in every tenth patient. Even in cases of closure of trophic defects, the risk of recurrence is high. The article tells about the use of Actovegin®, its mechanism of action at different levels, as well as the etiology of CVI and its complicated forms, the appropriateness and adequacy of medical treatment with Actovegin®.